89489-53-2

Usage

Uses

Used in Pharmaceutical Industry:
2H-Thiopyran-4-carboxylic acid, tetrahydro-(9CI), is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2H-Thiopyran-4-carboxylic acid, tetrahydro-(9CI), serves as a precursor for the production of novel agrochemicals. Its incorporation into these compounds can enhance their effectiveness in pest control and crop protection, contributing to sustainable agricultural practices.
Used in Materials Science:
2H-Thiopyran-4-carboxylic acid, tetrahydro-(9CI), is employed in materials science for the development of innovative materials with unique properties. Its sulfur-containing structure can contribute to the creation of materials with enhanced stability, reactivity, or other desirable characteristics for specific applications.

InChI:InChI=1/C6H10O2S/c7-6(8)5-1-3-9-4-2-5/h5H,1-4H2,(H,7,8)

Upstream product

• 856939-74-7 tetrahydro-thiopyran-4-carboxylic acid ethyl ester 
• 1072-72-6 Tetrahydrothiopyran-4-one 
• 857778-39-3 4-bromo-2-(2-bromo-ethyl)-butyric acid ethyl ester 
• 67139-90-6 tetrahydro-2H-thiopyran-4-yl methane sulfonate 
• 128094-82-6 tetrahydro-thiopyran-4-carboxylic acid methyl ester 
• 195503-40-3 tetrahydro-2H-thiopyrane-4-carbonitrile 

Downstream Products

• 121654-84-0 tetrahydro-2H-thiopyran-4-carbonyl chloride 
• 64096-87-3 1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-carboxylic acid 
• 167011-48-5 tetrahydro-thiopyran-4-carboxylic acid amide 
• 128094-82-6 tetrahydro-thiopyran-4-carboxylic acid methyl ester 
• 100277-27-8 (tetrahydro-2H-thiopyran-4-yl)methanol 
• 1190861-82-5 N'-(3-bromophenyl)tetrahydro-2H-thiopyran-4-carbohydrazide 
• 1257249-79-8 C₃₀H₃₇FN₄OS 
• 473254-28-3 (1,1-dioxo-hexahydro-1-thiopyran-4-yl)-methanol 
• 928149-12-6 (1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl 4-methylbenzenesulfonate 

Relevant academic research and scientific papers

Expansion of substrate scope for nitroxyl radical/copper-catalyzed aerobic oxidation of primary alcohols: A guideline for catalyst selection

Four distinctive sets of optimum nitroxyl radical/copper salt/additive catalyst combinations have been identified for accommodating the aerobic oxidation of various types of primary alcohols to their corresponding aldehydes. Interestingly, less nucleophilic catalysts exhibited higher catalytic activities for the oxidation of particular primary allylic and propargylic alcohols to give α,β-unsaturated aldehydes that function as competent Michael acceptors. The optimum conditions identified herein were successful in the oxidation of various types of primary alcohols, including unprotected amino alcohols and divalent-sulfur-containing alcohols in good-to-high yields. Moreover, N-protected alaninol, an inefficient substrate in the nitroxyl radical/ copper-catalyzed aerobic oxidation, was oxidized in good yield. On the basis of the optimization results, a guideline for catalyst selection has been established.

SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR

Provided is a sulfonyl-substituted bicyclic compound (A) which acts as a RORγ inhibitor, said compound has good RORγ inhibitory activity and is expected to be used for treating diseases mediated by a RORγ receptor in mammals.

TRICYCLIC SULFONES AS ROR GAMMA MODULATORS

There are described RORγ modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES

The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the μ opioid receptor and/or the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.

Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists

Novel 3-(1H-indol-3-yl)-1,2,4-oxadiazoles and -thiadiazoles were synthesized and found to be potent CB1 cannabinoid receptor agonists. The oral bioavailability of these compounds could be dramatically improved by optimization studies of the side chains attached to the indole and oxadiazole cores, leading to identification of a CB1 receptor agonist with good oral activity in a range of preclinical models of antinociception and antihyperalgesia.

INDOLE DERIVATIVES

The invention relates to indole derivative having the general Formula I wherein A represents a 5-membered aromatic heterocyclic ring, wherein X1, X2 and X3 are independently selected from N, O, S and CH; Y represents CH2, O, S or SO2; R1 is H, (C1-4)-alkyl, (C1-4)alkyloxy, CN or halogen; R2, R2′, R3, R3′, R4, R4′, R5 and R5′ are independently hydrogen, (C1-4)alkyl (optionally substituted with OH) or CO—OR8; or one pair of geminal substituents R3 and R3′ or R5 and R5′ together represent a keto group, and the others are all hydrogen or (C1-4)alkyl; or R2 and R5 together represent a methylene or an ethylene bridge, and R2′, R3, R3′, R4, R4′ and R5′ are hydrogen; n is 1 or 2; R6 is H, (C1-4)alkyl (optionally substituted with OH(C1-4)alkyloxy, CO—NR9R10, CO—OR11 or 1,2,4-oxadiazol-3-yl), SO2NR12R13 or COOR14; R7 is H or halogen; R8 is (C1-4)alkyl; R9 and R10 are independently hydrogen, (C1-4)alkyl or (C3-7)cycloalkyl, the alkyl groups being optionally substituted with OH or (C1-4)alkyloxy; R11 is H or (C1-4)alkyl; R12 and R13 are independently H or (C1-4)alkyl; R14 is (C1-6)alkyl; or a pharmaceutically acceptable salt thereof, as agonists of the cannabinoid CB1 receptor, which can be used in the treatment of pain such as for example peri-operative pain, chronic pain, neuropathic pain, cancer pain and pain and spasticity associated with multiple sclerosis.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF

It is intended to provide a compound represented by the general formula (I): (I) (wherein all the symbols are as defined in the description) which has a p38 MAP kinase inhibitory activity, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. The compound of the invention is useful for preventing or treating a disease in which the abnormal production of a cytokine such as an inflammatory cytokine or a chemokine or overreaction to them is considered to be involved in the cause and aggravation of pathological conditions, in other words, an inflammatory disease, a respiratory disease, a cardiovascular disease, a central nervous system disease or the like, which is a cytokine-mediated disease.

SYNERGISTIC COMBINATION FOR THE TREATMENT OF PAIN (CANNABIOID RECEPTOR AGONIST AND OPIOD RECEPTOR AGONIST)

The invention relates to a pharmaceutical dosage form comprising an analgesic combination for simultaneous or sequential use which comprises a peripherally restricted cannabinoid CB1 receptor agonist having a brain Cmax to plasma Cmax ratio of less than 0

(INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR

The invention relates to indole derivative having the general Formula (I) Wherein A, X1, X2, X3, Y, R1, R2, R3 and R4 are as defined in the claims, or a pharmaceutically acceptab

Indole derivatives

Disclosed herein are indole derivatives of the formula (I) wherein each of the substitutents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the indole derivatives and use of